By Bhanvi Satija and Patrick Wingrove
(Reuters) -Eli Lilly on Thursday downplayed CVS Health (NYSE: CVS )’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell more than 10%.
CVS said its pharmacy benefit management unit, which is the largest in the U.S., would drop Zepbound coverage from July 1, but keep reimbursing for rival GLP-1 weight-loss drug Wegovy after negotiating a more favorable price from Danish drugmaker Novo Nordisk (NYSE: NVO ).
Lilly CEO Dave Ricks said on an investor call that those affected most by the CVS move would be small employers, many of which do not currently cover obesity drugs.
"It seems like the wrong idea to reduce choice," he said, adding that we will see how the market reacts.
Pharmacy benefit managers negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, and create lists of medications that are covered by insurance. Prescriptions can be drastically reduced if these middlemen decide not to cover a drug.
Lilly also said current tariffs imposed by the Trump administration would not materially affect its forecast for 2025. It said an expansion of import duties in other geographies or retaliatory tariffs would have a negative impact.
Daniel Barasa, a portfolio manager at Gabelli Funds, said the stock reaction to the CVS news is overblown, given larger self-insured employers typically design their own customized lists of drugs for reimbursement.
Two Lilly investors said the CVS coverage decision will heat up the pricing competition between Novo and Lilly. But they were not immediately worried about a big hit to sales as patients and doctors seem to prefer Zepbound, they said.
"There’s always the risk of a price competition when your competitor Novo Nordisk is frankly not doing enough with its pipeline. So they may try to get a bit too aggressive on pricing just to maintain market share," said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares.
The next two largest U.S. PBMs - UnitedHealth Group (NYSE: UNH )’s OptumRx and Cigna (NYSE: CI )’s Express Scripts - did not respond to queries about whether they were considering similar moves.
The success of Lilly’s popular weight-loss and diabetes treatments has made the Indianapolis-based drugmaker the world’s most valuable healthcare company, with a market value of more than $800 billion.
Lilly on Thursday also posted higher-than-expected quarterly results.
It said lower prices for Zepbound trimmed revenue in the quarter, but that demand remained strong. Sales of the drug came in at $2.31 billion for the first quarter, slightly below analysts’ expectations of $2.33 billion, according to LSEG data.
Lilly in February cut the price for vials of Zepbound by $50 or more and expanded the range of doses it sold online to address competition from compounding pharmacies and Novo. It now offers the two lowest doses of Zepbound for $349 and $499 for a month’s supply.
OVERTAKING WEGOVY
Weekly U.S. prescriptions of Wegovy have plateaued since mid-February, according to IQVIA data provided by analysts. Zepbound recorded nearly 339,000 prescriptions for the week ending April 18, overtaking Novo’s obesity drug by more than 127,000.
Lilly said it had captured about 53.3% of the U.S. market share. IQVIA data suggested Lilly’s current share was closer to 62%.
Leerink analyst David Risinger said CVS’ coverage decision will "hurt Zepbound’s growth momentum," although Lilly will maintain a leading market share as Zepbound has been shown to be a more effective drug than Wegovy.
"I would assume that Lilly will fortify its relationships with other major PBMs," he said.
Sales of diabetes drug Mounjaro were $3.84 billion, exceeding analysts’ estimates of $3.80 billion. Mounjaro is also the brand name used for weight loss outside the U.S.
Lilly cut its full-year adjusted profit forecast to between $20.78 and $22.28 per share, from its previous view of $22.50 to $24.00 per share, citing deal charges.
On an adjusted basis, Lilly earned $3.34 per share for the quarter, topping analysts’ estimates by 32 cents.
Total revenue for the period was $12.73 billion, above Wall Street expectations of $12.67 billion.